40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +1 415 735 3289

In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. With the field anticipating finalized regulatory guidelines from the FDA, the need to link mechanisms of action to potency assays scientifically has never been more urgent.

At the 4th Cell Therapy Potency Assay Summit, we unite analytical development, quality control, and regulatory experts to tackle these pressing issues. Our goal is to collaboratively design robust potency assays that not only conform to changing guidelines but also streamline patient access to the next generation of cell therapies.

Whether you are preparing for your first IND or gearing up for BLA submission, this summit offers an unparalleled opportunity to gain insights from leading organizations like Arsenal Biosciences, BlueRock Therapeutics, the NIST and Vertex Pharmaceuticals.

Join us this March to equip your team with the industry and academic insights needed to develop practical and reproducible assays, providing a deeper understanding of your cell therapy products for autologous and allogeneic therapies across various cell types and indications.

URLs:
Tickets: https://go.evvnt.com/2741227-2?pid=1052
Brochure: https://go.evvnt.com/2741227-3?pid=1052

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Workshop Day: USD 3597.00,
Academic Pricing - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + Workshop Day: USD 5097.00,
Solution Provider Pricing - Conference Only: USD 3699.00

Alison Caldwell, Group Leader- Analytical Development, Resolution Therapeutics, Anna Brown, Director Analytical Development, Poseida Therapeutics, Anthony Garcia, Head of Quality Control, Kiromic BioPharma, Briti Saha, Senior Scientist - Analytical Sciences and Technology, Century Therapeutics, Carl Simon, Biologist Professional, National Institute of Standards and Technology (NIST), Connie Tsai, Associate Director - Analytical Development, Novartis, Devika Schirloff, Associate Director - Chemistry, Manufacturing, and Controls, BobcatBio, Hui Wen Liu, Principal Scientist - Assay Development, Affini-T Therapeutics, Jie Wei, Director - Bioanalytical Sciences, Tr1x Bio, John Yu, Director - Analytical Development and Cell Process Sciences, Arcellx, Jorge S. Burns, Associate Professor, University of Ferrara, Jose Pena, Principal Scientist, Arsenal Bio, Kathy Simon, Vice President - Global Quality, Cellectis, Kelly Bowen, Associate Principal Scientist - Analytical Development, Technical Operations, KSQ Therapeutics, Melanie Grant, Director - Correlative Studies Lab, Marcus Center for Advanced Cell and Gene Therapies, Emory University School of Medicine, Sebastian Hymson, Scientist, BioNTech, Serena Hamada, Scientist, Bristol Myers Squibb, Shawna Organ, Senior Scientist – Assay Development, BlueRock Therapeutics, Suning Wang, Senior Scientist, Vertex Pharmaceuticals, Xiaoya Sun, Scientist - Analytical Development - Cell Therapy, Takeda